Client NewsRoquefort Therapeutics PLC: Proposed Acquisition of Oncogeni Limited & Placing
Roquefort Therapeutics plc (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to announce that it has entered into a conditional share sale and purchase agreement (the “Acquisition Agreement”) with the shareholders of Oncogeni Limited, a UK biotech company developing novel patented cancer medicines, (the “Sellers”) pursuant to which Roquefort Therapeutics has agreed to acquire the entire issued share capital of Oncogeni Limited (“Oncogeni”) for an aggregate consideration to be satisfied by the issue of 50,000,000 new ordinary shares in the Company (“Consideration Shares”) to the Sellers (the “Acquisition”).
OPEN AN ACCOUNT
If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.
Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.